SCHEMBL3579322

SCHEMBL3579322

CC(C)Oc1cccc(-c2cc(CC(=O)O)cc(OCc3ccccc3)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.52
LTB4R Q15722 1/20 0.51
LTB4R2 Q9NPC1 1/20 0.51
FFAR4 Q5NUL3 4/20 0.50
MCL1 Q07820 1/20 0.49
NR4A2 P43354 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.49
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
PPARD Q03181 3/20 0.48
PPARG P37231 1/20 0.48
CTSA P10619 1/20 0.47
F11 P03951 1/20 0.47
TPSB2 P20231 1/20 0.47
FFAR1 O14842 3/20 0.47
AKR1B1 P15121 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
MAOB P27338 1/20 0.46
SLC13A5 Q86YT5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563479 0.91 MCL1 (0.60) LTB4RLTB4R2FFAR4MCL1PPARD
SCHEMBL3566811 0.88 FFAR1 (0.59) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3569632 0.86 PPARG (0.62) CFDLTB4RLTB4R2FFAR4MCL1
SCHEMBL3565506 0.85 FFAR1 (0.60) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3576903 0.85 CFD (0.53) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3908596 0.83 CFD (0.66) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3567254 0.83 FFAR1 (0.56) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3569938 0.83 CFD (0.51) CFDLTB4RLTB4R2FFAR4MCL1
SCHEMBL3578154 0.82 FFAR4 (0.51) CFDLTB4RLTB4R2FFAR4NR4A2
SCHEMBL3567039 0.81 PARP10 (0.52) CFDLTB4RLTB4R2FFAR4NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US claimed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US claimed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP claimed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP claimed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO claimed
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US disclosed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US disclosed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP disclosed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP disclosed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof BACE1, BACE2, APP CFD 3860/4885LTB4R 1634/4885LTB4R2 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.